Literature DB >> 730824

Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis.

H A Isomäki, T Hakulinen, U Joutsenlahti.   

Abstract

Entities:  

Mesh：

Year:  1978        PMID： 730824     DOI： 10.1016/0021-9681(78)90071-1

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN： 0021-9681


× No keyword cloud information.
  67 in total

1.  Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low.

Authors:  R J Farrell; Y Ang; P Kileen; D S O'Briain; D Kelleher; P W Keeling; D G Weir
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 2.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; M Dougados; P Emery; A Gibofsky; A F Kavanaugh; E C Keystone; L Klareskog; A S Russell; L B A van de Putte; M H Weisman; A F Kavenaugh
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

3.  Leukemia, lymphoma, and multiple myeloma following selected medical conditions.

Authors:  M M Doody; M S Linet; A G Glass; G D Friedman; L M Pottern; J D Boice; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1992-09       Impact factor: 2.506

4.  Non-Hodgkin's lymphoma in rheumatoid arthritis.

Authors:  D Porter; R Madhok; H Capell
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

5.  Beware of the biologicals--hospitals may die: the Rheumatism Foundation Hospital, Heinola, Finland (1951-2010).

Authors:  Markku J Kauppi; Hanna Säilä; Eero A Belt; Markku Hakala
Journal:  Clin Rheumatol       Date:  2012-05-27       Impact factor: 2.980

6.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis.

Authors:  R M Fleischmann; J Tesser; M H Schiff; J Schechtman; G-R Burmester; R Bennett; D Modafferi; L Zhou; D Bell; B Appleton
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

7.  Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.

Authors:  M H Schiff; G R Burmester; J D Kent; A L Pangan; H Kupper; S B Fitzpatrick; C Donovan
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

Review 8.  New perspectives of secondary and tertiary therapy for rheumatoid arthritis.

Authors:  R F Willkens
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

9.  Risk of cancer among rheumatoid arthritis patients in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2009-01-28       Impact factor: 2.506

Review 10.  Biologic treatments for systemic rheumatic diseases.

Authors:  Y Shirota; G G Illei; N P Nikolov
Journal:  Oral Dis       Date:  2008-02-14       Impact factor: 3.511
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.